Pharmacologic and Procedural Differences in the Management of Hidradenitis Suppurativa by Demographic Group: A Global TriNetX Analysis

Abstract

Keywords

hidradenitis suppurativa disparities biologics opiates inflammatory skin disease

Get full access to this article

View all access options for this article.

References

Alotaibi

HM.

Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. doi:10.2147/CCID.S402453

Desir

Encarnacion

Ogunleye

Taylor

SC.

Hidradenitis suppurativa disproportionately affects marginalized groups: an all of us database analysis. J Cutan Med Surg. 2025;29(5):536-537. doi:10.1177/12034754251320635

Kilgour

Sarin

. Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: a retrospective analysis of 2 U.S. cohorts. JAAD Int. 2021;3:42-52. doi:10.1016/j.jdin.2021.01.007

Murray

Truman

Milligan

Modi

Adlard

Equity and outcome events in hidradenitis suppurativa: exploring effect modifiers associated with diagnostic delay in the real world. Dermatol Ther. 2024;14(12):3211-3227. doi:10.1007/s13555-024-01291-0

Barnes

Shukla

Paul

, et al. Patient perspectives of health system barriers to accessing care for hidradenitis suppurativa: a qualitative study. JAMA Dermatol. 2023;159(5):510-517. doi:10.1001/jamadermatol.2023.0486

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB